Evaluation of Serum Albumin-Coated Bone Allograft for Bone Regeneration: A Seven-Year Follow-Up Study of 26 Cases

We have previously reported that serum albumin-coated bone allograft (BoneAlbumin, BA) is an effective bone substitute. It improves bone regeneration at the patellar and tibial donor sites six months after harvesting bone-patellar tendon-bone (BPTB) autografts for primary anterior cruciate ligament...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of molecular sciences Vol. 24; no. 11; p. 9232
Main Authors:	Gyulay, Kata K, Karászi, Péter, Rédei, Mátyás, Sólymos, Petra, Schandl, Károly, Lacza, Zsombor, Horváthy, Dénes B
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 25-05-2023 MDPI
Subjects:	Albumin Allografts Anterior cruciate ligament Autografts Biocompatibility Biomedical materials Blood coagulation bone allograft Bone density Bone grafts Bone growth bone substitute BoneAlbumin bone–tendon–bone autograft BTB Cancellous bone Clinical outcomes Computed tomography Cortical bone Disease transmission Electronics industry Evaluation Medical research Medicine, Experimental Orthopedic surgery Regeneration Regeneration (physiology) Serum albumin Skin & tissue grafts Stem cells Substitute bone Surgery Thickness Tomography Transplantation of organs, tissues, etc Transplants & implants Hungary Netherlands BTB bone substitute bone allograft donor site morbidity BoneAlbumin serum albumin bone–tendon–bone autograft radiomorphology anterior cruciate ligament replacement
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We have previously reported that serum albumin-coated bone allograft (BoneAlbumin, BA) is an effective bone substitute. It improves bone regeneration at the patellar and tibial donor sites six months after harvesting bone-patellar tendon-bone (BPTB) autografts for primary anterior cruciate ligament reconstruction (ACLR). In the present study, we examined these donor sites seven years after implantation. The study group (N = 10) received BA-enhanced autologous cancellous bone at the tibial and BA alone at the patellar site. The control group (N = 16) received autologous cancellous bone at the tibial and blood clot at the patellar site. We evaluated subcortical density, cortical thickness, and bone defect volume via CT scans. At the patellar site, subcortical density was significantly higher in the BA group at both time points. There was no significant difference in cortical thickness between the two groups at either donor site. The control group's bone defect significantly improved and reached the BA group's values at both sites by year seven. Meanwhile, the bone defects in the BA group did not change significantly and were comparable to the six-month measurements. No complications were observed. There are two limitations in this study: The number of patients recruited is small, and the randomization of the patients could have improved the quality of the study as the control group patients were older compared to the study group patients. Our 7-year results seem to demonstrate that BA is a safe and effective bone substitute that supports faster regeneration of donor sites and results in good-quality bone tissue at the time of ACLR with BPTB autografts. However, studies with a larger number of patients are required to definitively confirm the preliminary results of our study.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work.
ISSN:	1422-0067 1661-6596 1422-0067
DOI:	10.3390/ijms24119232